Indium In 111 Pentetreotide
A radioactive imaging agent that combines indium-111 with pentetreotide, a compound that binds to somatostatin receptors found on certain tumors. It is used in nuclear medicine scans to detect and locate neuroendocrine tumors throughout the body.
Berat Molekul
1472,4000 g/mol
TPSA
553,00 Ų
Area Terapeutik
Mekanisme Kerja
Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN(CCN(CCC(C(=O)[O-])C(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)NC(CO)C(C)O)O.[111In+3]
InChI
InChI=1S/C62H84N12O19S2.In/c1-35(76)47(32-75)69-59(88)49-34-95-94-33-48(70-55(84)44(25-37-13-5-3-6-14-37)65-50(78)29-74(31-52(81)82)24-23-73(30-51(79)80)22-20-41(61(90)91)62(92)93)58(87)67-45(26-38-15-7-4-8-16-38)56(85)68-46(27-39-28-64-42-18-10-9-17-40(39)42)57(86)66-43(19-11-12-21-63)54(83)72-53(36(2)77)60(89)71-49;/h3-10,13-18,28,35-36,41,43-49,53,64,75-77H,11-12,19-27,29-34,63H2,1-2H3,(H,65,78)(H,66,86)(H,67,87)(H,68,85)(H,69,88)(H,70,84)(H,71,89)(H,72,83)(H,79,80)(H,81,82)(H,90,91)(H,92,93);/q;+3/p-4/i;1-4
Molecular Formula
C62H80InN12O19S2-
HBD / HBA
13 / 24
Ikatan yang Dapat Dirotasi
28
Atom Berat
96
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
A radioactive imaging agent that combines indium-111 with pentetreotide, a compound that binds to somatostatin receptors found on certain tumors. It is used in nuclear medicine scans to detect and locate neuroendocrine tumors throughout the body.
Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.
Yes, Indium In 111 Pentetreotide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200642. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 76871863. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="indium-in-111-pentetreotide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/indium-in-111-pentetreotide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/indium-in-111-pentetreotide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/indium-in-111-pentetreotide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="indium-in-111-pentetreotide"></drugfyi-drug>